Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. - Scribner JA; Hicks SW; Sinkevicius KW; Yoder NC; Diedrich G; Brown JG; Lucas J; Fuller ME; Son T; Dastur A; Hooley J; Espelin C; et al. (Molecular cancer therapeutics, 2022)